Client had recently acquired a CRO focusing on Phase 1-3 clinical trials for Pharma and Biotech customers. They were keen to augment the portfolio company’s capabilities by acquiring complementary assets in the US and also to broaden the services offering
We leveraged our IP to generate a comprehensive database of CROs offering services that could be considered complementary to the portfolio company. Based on our research, we identified, evaluated and prioritized over 200 add-on targets and initiated contact with selected potential targets.
Our client (mid-market private equity fund), managed to close 2 add-on deals for their CRO portfolio company, within a period of one year.
Quick Enquiry For
121/7E Avenue Franklin Roosevelt 1050 Brussels, Belgium